TrialBMC cancer2024

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302).

Primo N Lara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.